S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 094.5 JPY 1.72% Market Closed
Market Cap: 1.8T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Shionogi & Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shionogi & Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
S
Shionogi & Co Ltd
TSE:4507
Interest Income Expense
ÂĄ45.4B
CAGR 3-Years
28%
CAGR 5-Years
-1%
CAGR 10-Years
15%
Takeda Pharmaceutical Co Ltd
TSE:4502
Interest Income Expense
-ÂĄ175.7B
CAGR 3-Years
-15%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Interest Income Expense
ÂĄ24.3B
CAGR 3-Years
100%
CAGR 5-Years
60%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Interest Income Expense
ÂĄ20.5B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Interest Income Expense
ÂĄ39m
CAGR 3-Years
-54%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Interest Income Expense
-ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.8T JPY
Industry
Pharmaceuticals

Shionogi & Co. Ltd., a prominent Japanese pharmaceutical company founded in 1878, has established itself as a key player in the global healthcare landscape through its unwavering commitment to innovation and patient-centric solutions. With a rich history that spans over a century, Shionogi has evolved from its roots in traditional medicine to a forward-thinking biopharmaceutical enterprise. It focuses on developing treatments for infectious diseases, pain management, and central nervous system disorders, leveraging its cutting-edge research capabilities and extensive pipeline of drugs. The company's strategic emphasis on transformative therapies not only aims to tackle prevalent health issues but also positions Shionogi for sustainable long-term growth in a competitive market. For investors, Shionogi offers a compelling story marked by strong fundamentals and a robust pipeline. As the company continues to target unmet medical needs, its recent advancements in antiviral treatments, particularly against COVID-19, demonstrate its agility in responding to global health crises. With a solid balance sheet and a history of steady revenue growth, Shionogi is well-equipped to navigate the evolving pharmaceutical landscape. Moreover, the company's commitment to research and development, which accounts for a significant portion of its budget, signals a proactive approach toward future innovations. For those looking to invest in a company with a legacy of excellence and a forward-looking vision, Shionogi & Co. Ltd. represents an enticing opportunity that combines stability with the promise of growth.

Intrinsic Value
2 173.97 JPY
Undervaluation 4%
Intrinsic Value
Price
S

See Also

What is Shionogi & Co Ltd's Interest Income Expense?
Interest Income Expense
45.4B JPY

Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's Interest Income Expense amounts to 45.4B JPY.

What is Shionogi & Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
15%

Over the last year, the Interest Income Expense growth was -7%. The average annual Interest Income Expense growth rates for Shionogi & Co Ltd have been 28% over the past three years , -1% over the past five years , and 15% over the past ten years .

Back to Top